Research and Clinical Trials

The following are Industry Sponsored Clinical Research (ISR) currently conducted at the various centres. For further information, please contact the Principal Investigator.

TYPE TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Unresectable Abdominal or Pelvic Malignancy Hyperthermia in Treating Patients with Painful Unresectable Abdominal or Pelvic Malignancy (ADIPOLAB-001) University of Malaya Medical Centre (UMMC) Dr Ho Gwo Fuang
fuang@ummc.edu.​my
SC: Yok Yong 03-79492120 (Research Room) CLICK HERE

Early Stage Breast Cancer

TYPE TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
ER+, HER2- Early Stage Breast Cancer A Phase III, Randomized, open labelled, multicenter study evaluating the efficacy and safety of adjuvant giredestrant compared with physician’s choice of adjuvant endocrine monotheraphy in patients with estrogen receptor-positive, HER-2 negative early breast cancer (GO42784 – lidERA Breast Cancer) University of Malaya Medical Centre (UMMC) Dr Ho Gwo Fuang
fuang@ummc.edu.​my
SC: Alice 03-79492120 (Research Room) CLICK HERE
Beacon Hospital Sdn Bhd Dr Azura Rozila Ahmad drazura@beaconhospital.com.my
03 – 7787 2830
General line: 03 7620 7979 / 03 7787 2992 CRC: 03 -7787 2854 (Tel) / clinicalresearch@beaconhospital.com.my (Email)
Pantai Hospital Sungai Petani
Hospital Pulau Pinang

 

Advanced Breast Cancer

TYPE TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Subtype: HER2-Negative
HER2-negative with APOBEC3B Protein Phase II, Single Arm, Open Label, Simon Two-Stage Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients: Evaluation of Impact of Germline Variants in APOBEC3B (AUROR) University of Malaya Medical Centre (UMMC) Dr Ho Gwo Fuang
fuang@ummc.edu.​my
SC: Yok Yong 03-79492120
(Research Room)
CLICK HERE
Subtype: HER2-Positive
HER2+ Advanced Breast Cancer with PIK3CA Mutation A Two-part, Phase III, Multicenter, Randomized (1:1), Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination with Trastuzumab and Pertuzumab as Maintenance Therapy in Patients with HER2-Positive Advanced Breast Cancer with a PIK3CA Mutation (EPIK-B2) University of Malaya Medical Centre (UMMC) Dr Ho Gwo Fuang
fuang@ummc.edu.​my
SC: Kimee Ku 03-79492120
(Research Room)
CLICK HERE
Pantai Hospital Kuala Lumpur DR MASTURA BINTI MD YUSOF drmasturamy@gmail.com
03 – 2296 0764
General Line: 03 – 2296 0888
CRC: 03 – 2781 0888
Ext 4519/4520/4522
Beacon Hospital Sdn Bhd Dato’ Dr Mohamed Ibrahim A Wahid
03 – 7620 7979
03 – 7787 2992
(Ext: 2868)
General line: 03 7620 7979 /
03 7787 2992
CRC: 03 -7787 2854 (Tel) / clinicalresearch@beaconhospital.com.my
(Email)
Subtype: HR-Negative & HER2-negative (Triple Negative)
Homologous recombinat Deficiency Metastatic Breast Cancer in Asian Phase II Study to assess the efficacy of Talazoparib in asian mEtastatic breast caNcer patients with a hOmologous Recombinant deficiency (HRD) signature (TENOR) University of Malaya Medical Centre (UMMC) Dr Ho Gwo Fuang
fuang@ummc.edu.​my
SC: Wei Ying 03-79492120 (Research Room) CLICK HERE
Pantai Hospital Kuala Lumpur DR MASTURA BINTI MD YUSOF drmasturamy@gmail.com
03 – 2296 0764
General Line: 03 – 2296 0888 CRC: 03 – 2781 0888 Ext 4519/4520/4522
Sultan Ismail Hospital, Johor Bahru DR LIM CHUN SEN chunsen1@hotmail.com General line: 07 – 356 5000 CRC: 07 – 356 5155 (Tel) / 07 – 3565 5154 (Fax) / Sister Rafi’ah binti Othman Admin Manager crchsijb@gmail.com (Email)
Triple Negative Advnced Breast Cancer with PIK3CA Mutation and PTEN Loss A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Nab-paclitaxel in Patients With Advanced Triple Negative Breast Cancer With Either Phosphoinositide-3-kinase Catalytic Subunit Alpha (PIK3CA) Mutation or Phosphatase and Tensin Homolog Protein (PTEN) Loss Without PIK3CA Mutation (EPIK-B3) Pantai Hospital Kuala Lumpur DR MASTURA BINTI MD YUSOF drmasturamy@gmail.com
03 – 2296 0764
General Line: 03 – 2296 0888 CRC: 03 – 2781 0888 Ext 4519/4520/4522 CLICK HERE
University of Malaya Medical Centre (UMMC) DR ADLINDA ALIP adlinda@ummc.edu​.my SC: Yok Yong 03-79492120 (Research Room)
Beacon Hospital Sdn Bhd Dato’ Dr Mohamed Ibrahim A Wahid
03 – 7620 7979
03 – 7787 2992
(Ext: 2868)
General line: 03 7620 7979 / 03 7787 2992 CRC: 03 -7787 2854 (Tel) / clinicalresearch@beaconhospital.com.my (Email)
Subtype: HR-Positive & HER2-negative
ER+,HER2-Negative Advanced Breast Cancer Not Yet Received any Systemic Tretment A Randomised, Multicentre, Double-Blind, Phase III Study of AZD9833 (an Oral SERD) plus Palbociclib versus Anastrozole plus Palbociclib for the Treatment of Patients with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (SERENA-4) Pantai Hospital Kuala Lumpur DR JOHN LOW SENG HOOI john.low@pantaidr.my General Line: 03 – 2296 0888 CRC: 03 – 2781 0888 Ext 4519/4520/4522 CLICK HERE
University of Malaya Medical Centre (UMMC) Dr Ho Gwo Fuang
fuang@ummc.edu.​my
SC: Kimee Ku 03-79492120 (Research Room)
SC: Wei Ying 03-79492120 (Research Room)
Kuala Lumpur Hospital (HKL) Dr Vaishnavi Jeyasingam vaishnavijeyasingam@yahoo.com General line: 03 – 2615 5555 CRC: 03 – 2615 5555 Ext. 6262 (Tel) / crc.hkl@moh.gov.my (email) / Crc Hkl / Clinical Research Centre HKL (Facebook
Sarawak General Hospital DR Syadwa Binti Abdul Shukor assyadwa@gmail.com General line: 03 – 2615 5555 CRC: 03 – 2615 5555 Ext. 6262 (Tel) / crc.hkl@moh.gov.my (email) / Crc Hkl / Clinical Research Centre HKL (Facebook
Pulau Pinang Hospital DR CHOONG SWEE HSIA shchoong83@gmail.com General line: 03 – 2615 5555 CRC: 03 – 2615 5555 Ext. 6262 (Tel) / crc.hkl@moh.gov.my (email) / Crc Hkl / Clinical Research Centre HKL (Facebook
Sultan Ismail Hospital, Johor Bahru DR CHOONG SWEE HSIA shchoong83@gmail.com General line: 07 – 356 5000 CRC: 07 – 356 5155 (Tel) / 07 – 3565 5154 (Fax) / Sister Rafi’ah binti Othman Admin Manager crchsijb@gmail.com (Email)
HR+, HER2- Locally Recurrent Inoperable Metastic Breast Cancer Failed Endocrine Therapy for Chemotherapy-Candidate A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49) Pantai Hospital Kuala Lumpur DR MASTURA BINTI MD YUSOF drmasturamy@gmail.com
03 – 2296 0764
General Line: 03 – 2296 0888 CRC: 03 – 2781 0888 Ext 4519/4520/4522 CLICK HERE
University of Malaya Medical Centre (UMMC) DR NUR FADHLINA ABDUL SATAR
fadhlinas@ummc.edu.my
SC: Kimee Ku 03-79492120 (Research Room)
Kuala Lumpur Hospital (HKL) Dr Eznal Izwadi Mohd Mahidin eznal.mahidin@gmail.com General line: 03 – 2615 5555 CRC: 03 – 2615 5555 Ext. 6262 (Tel) / crc.hkl@moh.gov.my (email) / Crc Hkl / Clinical Research Centre HKL (Facebook)
Hospital Pulau Pinang Dr Tan Ai Lian ailian.tan@gmail.com General line: 03 – 2615 5555 CRC: 03 – 2615 5555 Ext. 6262 (Tel) / crc.hkl@moh.gov.my (email) / Crc Hkl / Clinical Research Centre HKL (Facebook)
Sarawak General Hospital DR VOON PEI JYE voonpj@yahoo.com ‘General line: 082 – 276666 CRC: 082-276820 (Tel) / 082-276823 (Fax) / Tiong Lee Len, Admin Manager leelen.crc@gmail.com, crcsghkuching@gmail.com (Email) / https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480/ (Facebook)
TYPE TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Adult women with Platinum Resisitant or Refractory High-Grade Serous Ovarian Cancer with No BRCA Germline Mutated A Phase III, Multi-center, Randomized (1:1), Open-label, Active-controlled, Study to Assess the Efficacy and Safety of Alpelisib (BYL719) in Combination With Olaparib as Compared to Single Agent Cytotoxic Chemotherapy, in Participants With no Germline BRCA Mutation Detected, Platinum-resistant or Refractory, High-grade Serous Ovarian Cancer (EPIK-O) University of Malaya Medical Centre (UMMC) DR ROZITA ABDUL MALIK rozita@ummc.edu.my SC: Yok Yong
03-79492120
(Research Room)
CLICK HERE
Kuala Lumpur Hospital (HKL) DR NOOR ZAFIFAH BINTI ZAKARIA
zazajaka@gmail.com
General line:
03 – 2615 5555
CRC: 03 – 2615 5555 Ext. 6262 (Tel) / crc.hkl@moh.gov.my (email) /
Crc Hkl / Clinical Research Centre HKL (Facebook)
Hospital Wanita dan Kanak-Kanak Sabah DR SOON RUEY rueysoon@yahoo.com General line:
08 – 8522 600 Ext. 2272

Head & Neck Cancer

TYPE TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
HRAS Mutation The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma (HNSCC) with HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN) (KO-TIP-007) University of Malaya Medical Centre (UMMC) DR NUR FADHLINA ABDUL SATAR
fadhlinas@ummc.edu.my
SC: Kimee Ku
03-79492120
(Research Room)
CLICK HERE
National Cancer Institute (IKN) DR SUHANA BINTI YUSAK drsuhana@nci.gov.my General line : 03 – 8892 5555
CRC: 03 – 8892 5555 Ext 4168 (Tel) /
03- 8892 5622 (Fax) /
Siti Fatimah Zahra Mohd Anuar
Pengurus Pentadbiran
fatimahzahra@crc.moh.gov.my (Email)
Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma An Open Label Trial of BI 765063 in Combination With BI 754091 (Ezabenlimab) Alone or With BI 836880, Chemotherapy, or Cetuximab, in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) or Hepatocellular Carcinoma (HCC) Sarawak General Hospital General line: 082 – 276666
CRC: 082-276820
(Tel) / 082-276823 (Fax) /
Tiong Lee Len, Admin Manager leelen.crc@gmail.com (Email) / https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480/ (Facebook)
CLICK HERE

 

Thyroid Cancer

TYPE TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Locally Advaanced or Metastatic BRAFV600E Mutation-Positive, Differentiated Thyroid Carcinoma Who Are Refractory to Radioactive Iodine and Have Progressed following Prior VEGFR Targeted Therapy A Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Dabrafenib plus Trametinib in Previously Treated Patients with Locally Advanced or Metastatic, Radio-Active Iodine Refractory BRAFV600E Mutation-Positive Differentiated Thyroid Cancer (CDRB436J12301) Pantai Hospital Kuala Lumpur DR JOHN LOW SENG HOOI john.low@pantaidr.my General Line: 03 – 2296 0888
CRC: 03 – 2781 0888
Ext 4519/4520/4522
CLICK HERE
University of Malaya Medical Centre (UMMC) DR WAN ZAMANIAH wzamaniah@ummc.edu.my SC: Yok Yong
03-79492120
(Research Room)
Kuala Lumpur Hospital DR IBTISAM MUHAMAD NOR maryamsofiyyah@yahoo.com.my General line: 03 – 2615 5555
CRC: 03 – 2615 5555 Ext. 6262 (Tel) / crc.hkl@moh.gov.my (email) /
Crc Hkl / Clinical Research Centre HKL (Facebook)
Hospital Pulau Pinang DR CHOONG SWEE HSIA shchoong83@gmail.com General line: 04-2225 333
CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586 –
Dr. Yoon Chee Kin
Ketua Jabatan
dryoonck@moh.gov.my (email)
Sister Zarina Bt Che Umar
Admin Manager
zarinacu@gmail.com (Email)
Sarawak General Hospital DR HADI BIN AB.JALIL hadiabjalil@gmail.com General line:
082 – 276666
CRC: 082-276820 (Tel) /
082-276823 (Fax) /
Tiong Lee Len, Admin Manager leelen.crc@gmail.com (Email) / https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480/ (Facebook)
TYPE TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Locally Advanced or metastatic Hepatocellular Carcinoma (HCC) Who Have Progressed On Prior Systemic Treatment with Atezolizumab plus Bevacizumab Combination. A phase III, open-label, randomized study of atezolizumab with lenvatinib or sorafenib versus lenvatinib or sorafenib alone in HCC previously treated with atezolizumab and bevacizumab (IMbrave251) University of Malaya Medical Centre (UMMC) Dr Ho Gwo Fuang fuang@ummc.edu.​my SC: Alice 03-79492120
(Research Room)
CLICK HERE
Beacon Hospital Dr Tho Lye Mun tholm@beaconhospital.com.my General line: 03 7620 7979 /
03 7787 2992
CRC: 03 -7787 2854 (Tel) / clinicalresearch@beaconhospital.com.my (Email)
Participant with Complete Radiological Response after Surgical Resection and Local Ablation A Phase 3 Double-blinded, Two-arm Study to Evaluate the Safety and Efficacy of Pembrolizumab (MK-3475) versus Placebo as Adjuvant Therapy in Participants with Hepatocellular Carcinoma and Complete Radiological Response after Surgical Resection or Local Ablation (KEYNOTE-937) National Cancer Institute (IKN) DR WONG YOKE FUI, Florence dryfwong@nci.gov.my General line : 03 – 8892 5555
CRC: 03 – 8892 5555
Ext 4168 (Tel) /
03- 8892 5622 (Fax) /
Siti Fatimah Zahra Mohd Anuar Pengurus Pentadbiran fatimahzahra@crc.moh.gov.my (Email)
CLICK HERE
Sarawak General Hospital DR LIM YUEH NI ynlim1001@yahoo.com General line: 082 – 276666
CRC: 082-276820 (Tel) /
082-276823 (Fax) /
Tiong Lee Len, Admin Manager leelen.crc@gmail.com (Email) / https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480/ (Facebook)
Adventist Penang Dr. Ang Soo Fan angsoofan@pah.com.my
04-222 7490/7491/7339
General line: 04-2227200
CRC: 04 222 7652 / 7653 (Tel) / researchcentre@pah.com.my (Email)
University of Malaya Medical Centre (UMMC) Dr Ho Gwo Fuang fuang@ummc.edu.​my SC: Alice 03-79492120
(Research Room)

Colorectal Cancer – Advanced Colorectal Cancer

TYPE TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Progressed after SOC with KRAS G12C Mutation A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (Krystal-10) Beacon Hospital Sdn Bhd Dato’ Dr Mohamed Ibrahim A Wahid dribrahim@beaconhospital.com.my
03 – 7620 7979
03 – 7787 2992
(Ext: 2868)
General line: 03 7620 7979 / 03 7787 2992
CRC: 03 -7787 2854 (Tel) / clinicalresearch@beaconhospital.com.my (Email)
CLICK HERE

 

Colorectal Cancer – Early Stage Colorectal Cancer

TYPE TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Dukes C and High Risk Dukes B Colorectal Cancers Aspirin for Dukes C and High Risk Dukes B Colorectal Cancers (ASCOLT) University of Malaya Medical Centre (UMMC) Dr Ho Gwo Fuang
fuang@ummc.edu.​my
SC: Kimee Ku 03-79492120
(Research Room)
SC: Alice 03-79492120
(Research Room)
CLICK HERE
TYPE TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Non Small Cell Lung Cancer with Cmplete Resection Stge 1A2 and 1A3 and EGFR Mutation A Phase III, Double blind, Randomised, Placebo Controlled, International Study to assess the Efficacy and Safety of Adjuvant Osimertinib versus Placebo in Participants with EGFR mutation positive Stage IA2 IA3 Non small Cell Lung Cancer, following Complete Tumour Resection (ADAURA2) Pantai Hospital Kuala Lumpur DR MASTURA BINTI MD YUSOF drmasturamy@gmail.com
03 – 2296 0764
General Line:
03 – 2296 0888
CRC: 03 – 2781 0888
Ext 4519/4520/4522
CLICK HERE
Beacon Hospital Sdn Bhd DR THO LYE MUN drtho.oncology@gmail.com General line:
03 7620 7979 / 03 7787 2992
CRC: 03 -7787 2854 (Tel) / clinicalresearch@beaconhospital.com.my (Email)
Hospital Pulau Pinang Dr Tan Ai Lian ailian.tan@gmail.com General line: ‘
04-2225 333 CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586 – Dr. Yoon Chee Kin, Ketua Jabatanآ dryoonck@moh.gov.my (email) Sister Zarina Bt Che Umar
Admin Manager zarinacu@gmail.com (Email)
Sarawak General Hospital DR VOON PEI JYE voonpj@yahoo.com General line: 082 – 276666 CRC: 082-276820 (Tel) / 082-276823 (Fax) / Tiong Lee Len, Admin Manager leelen.crc@gmail.com (Email) / https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480/ (Facebook)
NSCLC,, Advanced & Metastatic, First-line Treatment, HER2+ overexpressionn A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination With Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2+) (DESTINY-Lung03) University of Malaya Medical Centre (UMMC) DR HO GWO FUANG
fuang@ummc.edu.​my
SC: Alice 03-79492120
(Research Room)
CLICK HERE
NSCLC, Locally Advanced and Metastatic, EGFR mutation A single-arm, open-label, phase 2 study of Dacomitinib with or without dose titration for the first-line treatment of locally advanced or metastatic non-small cell lung cancer in subjects with an epidermal growth factor receptor (egfr) activation mutation (ATORG003) Beacon Hospital Sdn Bhd Dr Tho Lye Mun
drtho.oncology@gmail.com
General line:
03 7620 7979 / 03 7787 2992
CRC: 03 -7787 2854 (Tel) / clinicalresearch@beaconhospital.com.my (Email)
CLICK HERE
Sarawak General Hospital DR LIM YUEH NI
ynlim1001@yahoo.com
‘General line: 082 – 276666
CRC: 082-276820 (Tel) /
082-276823 (Fax) /
Tiong Lee Len, Admin Manager leelen.crc@gmail.com (Email) / https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480/ (Facebook)
University of Malaya Medical Centre (UMMC) DR HO GWO FUANG
fuang@ummc.edu.​my
SC: Yok Yong 03-79492120
(Research Room)
Non Small Cell Lung Cancer, Metastatic, Disease Progression after Treatment with Platinum Chemotherapy and Immunotherapy A Phase II, multicenter, randomized study to compare the efficacy and safety of MK-7684A or MK-7684A plus Docetaxel versus Docetaxel monotherapy in the treatment of participants with metastatic non-small cell lung cancer with progressive disease after treatment with a platinum doublet chemotherapy and immunotherapy (MK-7684A-003) Beacon Hospital Sdn Bhd Dr Junie Khoo Yu-Yen jkyy1081@gmail.com General line:
03 7620 7979 / 03 7787 2992
CRC: 03 -7787 2854 (Tel) / clinicalresearch@beaconhospital.com.my (Email)
CLICK HERE
Sultan Ismail Hospital, Johor Bahru DR LIM CHUN SEN chunsen1@hotmail.com General line: 07 – 356 5000
CRC:  07 – 356 5155 (Tel) /
07 – 3565 5154 (Fax) /
Sister Rafi’ah binti Othman Admin Manager crchsijb@gmail.com (Email)
Tengku Ampuan Afzan Hospital, Kuantan DR AISHAH BINTI IBRAHIM aishibr@gmail.com CRC: 09-5572923
Ext: 2922/2928 (Tel) /
09-5139378 (Fax) /
crchtaa@gmail.com  (Email)
Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer for First Line Treatment A Randomized, Double Blind, Phase 3 Study of Platinum-based Chemotherapy with or without INCMGA00012 in First-Line Metastatic Squamous and Nonsquamous Non-Small Cell Lung Cancer Participants (POD1UM 304) (INCMGA 0012-304) Beacon Hospital Sdn Bhd Dr Azura Rozila Ahmad General line: 03 7620 7979 / 03 7787 2992 CRC: 03 -7787 2854 (Tel) / clinicalresearch@beaconhospital.com.my (Email) CLICK HERE
Tengku Ampuan Afzan Hospital, Kuantan DR AISHAH BINTI IBRAHIM aishibr@gmail.com CRC: 09-5572923
Ext: 2922/2928 (Tel) /
09-5139378 (Fax) /
crchtaa@gmail.com  (Email)
Sarawak General Hospital  DR AIDEN HENG FOOK YEW hengfy.onco@gmail.com General line: 082 – 276666
CRC: 082-276820 (Tel) /
082-276823 (Fax) /
Tiong Lee Len, Admin Manager leelen.crc@gmail.com (Email) / https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480/ (Facebook)
Non Small Cell Lung Cancer, Locally Advanced or Metastatic, EGFR Mutation, First Line Treament Phase 3, Randomized Study of Amivantamab and Lazertinib Combination Therapy Versus Single Agent Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA) Tengku Ampuan Afzan Hospital, Kuantan PROF DR HOW SOON HIN how_sh@yahoo.com  CRC: 09-5572923
Ext: 2922/2928 (Tel) /
09-5139378 (Fax) /
crchtaa@gmail.com  (Email)
CLICK HERE
Sultan Ismail Hospital, Johor Bahru DR LIM CHUN SEN chunsen1@hotmail.com General line: 07 – 356 5000
CRC:  07 – 356 5155 (Tel) /
07 – 3565 5154 (Fax) /
Sister Rafi’ah binti Othman
Admin Manager
crchsijb@gmail.com (Email)
Kuala Lumpur Hospital (HKL) DR MUTHUKKUMARAN A/L THIAGARAJAN drmuthuk@gmail.com General line: 03 – 2615 5555
CRC: 03 – 2615 5555 Ext. 6262 (Tel) /  crc.hkl@moh.gov.my (email) /
Crc Hkl / Clinical Research Centre HKL (Facebook) SC: Amirah 017-233 6295
Pulau Pinang Hospital DR SOO HOO HWOEI FEN General line: ’04-2225 333
CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586
Dr. Yoon Chee Kin,
Ketua Jabatan
dryoonck@moh.gov.my (email)
Sister Zarina Bt Che Umar
Admin Manager
zarinacu@gmail.com (Email)
Beacon Hospital Sdn Bhd Dr Azura Rozila Ahmad General line: 03 7620 7979 / 03 7787 2992
CRC: 03 -7787 2854 (Tel) / clinicalresearch@beaconhospital.com.my (Email)
University of Malaya Medical Centre (UMMC) DR ADLINDA ALIP adlinda@ummc.edu​.my SC: Yok Yong  017 268 0664
Non Small Cell Lung Cancer, Locally Advanced or Metastatic, EGFR Exon 20ins Mutation A Randomized, Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared with Carboplatin-Pemetrexed, in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Papillon) Sultan Ismail Hospital, Johor Bahru DR LIM CHUN SEN chunsen1@hotmail.com General line: 07 – 356 5000
CRC:  07 – 356 5155 (Tel) /
07 – 3565 5154 (Fax) /
Sister Rafi’ah binti Othman
Admin Manager
crchsijb@gmail.com (Email)
CLICK HERE
Kuala Lumpur Hospital (HKL) DR MUTHUKKUMARAN A/L THIAGARAJAN drmuthuk@gmail.com General line: 03 – 2615 5555
CRC: 03 – 2615 5555 Ext. 6262 (Tel) /  crc.hkl@moh.gov.my (email) /  Crc Hkl / Clinical Research Centre HKL (Facebook) SC: Amirah 017-233 6295
Pulau Pinang Hospital DR SOO HOO HWOEI FEN hwoeifen@yahoo.com General line: ’04-2225 333
CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586 –
Dr. Yoon Chee Kin, Ketua Jabatan  dryoonck@moh.gov.my (email)
Sister Zarina Bt Che Umar
Admin Manager
zarinacu@gmail.com (Email)
University of Malaya Medical Centre (UMMC) DR ADLINDA ALIP adlinda@ummc.edu​.my SC: Cryst Sari 03-79492120
(Research Room)
Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, PD-L1 Positive, for First Line Treatment Phase 3 Study to Evaluate Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined with AB154 in Front-Line, PD-L1-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (ARC-10) University of Malaya Medical Centre (UMMC) Dr Ho Gwo Fuang fuang@ummc.edu.​my SC: Alice 03-79492120
(Research Room)
CLICK HERE
Pantai Hospital Kuala Lumpur DR JOHN LOW SENG HOOI john.low@pantaidr.my General Line: 03 – 2296 0888
CRC: 03 – 2781 0888
Ext 4519/4520/4522
Universiti Kebangsaan Malaysian Medical Centre (UKMMC) PROF DATO’ DR FUAD ISMAIL fuad2305@yahoo.com Sekretariat Penyelidikan Perubatan & Inovasi Pusat Perubatan Universiti Kebangsaan Malaysia :
03-9145 9480 / 9481 (Tel) /
03 – 9145 6634 (Fax) / sppi@ppukm.ukm.edu.my (Email)
Clinical Trial Ward (CTW):
03-9145 7160/7161 (Tel) /
03-9145 6635 (Fax)
Mount Miriam Cancer Hospital Penang Dr Ang Tick Suan angts@mountmiriam.com General line: 04 – 892 3999
Tengku Ampuan Afzan Hospital, Kuantan DR HOW SOON HIN how_sh@yahoo.com  CRC: 09-5572923
Ext: 2922/2928 (Tel) /
09-5139378 (Fax) /
crchtaa@gmail.com  (Email)
Pulau Pinang Hospital DR FONG CHIN HENG fongchinheng@gmail.com General line:
04-2225 333
CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586
Dr. Yoon Chee Kin,
Ketua Jabatan
dryoonck@moh.gov.my (email)
Sister Zarina Bt Che Umar
Admin Manager
zarinacu@gmail.com (Email)
Sarawak General Hospital DR LIM YUEH NI ynlim1001@yahoo.com General line: 082 – 276666
CRC: 082-276820 (Tel) /
082-276823 (Fax) /
Tiong Lee Len,
Admin Manager
leelen.crc@gmail.com (Email) / https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480/ (Facebook)
Kuala Lumpur Hospital (HKL) Dr Eznal Izwadi Mohd Mahidin eznal.mahidin@gmail.com General line: 03 – 2615 5555
CRC: 03 – 2615 5555
Ext. 6262 (Tel) /
crc.hkl@moh.gov.my (email) /
Crc Hkl / Clinical Research Centre HKL (Facebook)
Locally advanced or metastatic NSCLC A phase III randomized, controlled, open-label, multicenter, global study of capmatinib in combination with osimertinib versus platinum – pemetrexed based doublet chemotherapy in patients with locally advanced or metastatic NSCLC harboring EGFR activating mutations who have progressed on prior 1st / 2nd generation EGFR‑TKI or osimertinib therapy and whose tumors are T790M mutation negative and harbor MET amplification (GEOMETRY-E) Sunway Medical Centre Dr. Jennifer Leong CRC: 03-8601 1079 (Tel) /
03-8601 1069 (Fax) /
sunmed-crc@sunway.cm.my edwinbt@sunway.com.my (email)
CLICK HERE
Non-small Cell Lung Cancer, Locally Advanced or Metastatic KRAS G12C Mutant, Previously Treated A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer (KontRASt-02) Sunway Medical Centre Dr Kow Ken Siong edwinbt@sunway.com.my (Email)
+603 – 74919191/ 603-8601 1081
CLICK HERE
NSCLC, Locally Advanced and Metastatic, Osimertinib Failure A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2) Mount Miriam Cancer Hospital Penang Dr Ang Tick Suan angts@mountmiriam.com
04-8923907
General line: 04 – 892 3999 CLICK HERE
TYPE TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Sarcoma/Solid Tumor Malignacies Immune Modulatory Effect of Hyperthermia During Treatment of Recurrent or Metastatic Solid Organ Malignancies (ADIPOLAB-002) University of Malaya Medical Centre (UMMC) Dr Ho Gwo Fuangfuang@ummc.edu.​my SC: Kimee Ku
03-79492120 (Research Room)
SC: Wei Ying
03-79492120 (Research Room)
N/A

Bladder Cancer

TYPE TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Cisplatin-eligible participants with muscle-invasive bladder cancer A Phase 3, Randomized, Open-Label Study to Evaluavate Perioperative Enfortumab Vedotin plus Pembrolizumab (MK-3475) versus Neodjuvant gemcitabine and cisplatin in cisplatin-eligible participants with muscle-invasive bladder cancer (KEYNOTE-B15/EV-304) University of Malaya Medical Centre (UMMC) DR MARNIZA SAAD Cryst Sari
03-79492120 (Research Room)
CLICK HERE
Cisplatin-ineligible participants with muscle-invasive bladder cancer A Randomized phase 3 study evaluating cystectomy with perioperative pembrolizumab and cystectomy with perioperative enfortumab vedotin and pembrolizumab versus cystectomy alone in cisplatin-ineligible participants with muscle-invasive bladder cancer (KEYNOTE 905) University of Malaya Medical Centre (UMMC) DR MARNIZA SAAD Cryst Sari
03-79492120 (Research Room)
CLICK HERE
Muscle-invasive bladder cancer A phase 3, randomized, double-blind, placebo-controlled clinical trial to study the efficacy and safety of pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) versus CRT alone in participants with muscle-invasive bladder cancer (MIBC) (KEYNOTE 992) Kuala Lumpur Hospital (HKL) DR MUTHUKKUMARAN A/L THIAGARAJAN General line:
03 – 2615 5555
CRC: 03 – 2615 5555 Ext. 6262 (Tel)
SC: Amirah 017-233 6295
CLICK HERE
University of Malaya Medical Centre (UMMC) DR MARNIZA SAAD SC: Cryst Sari
03-79492120
(Research Room)
Sunway Medical Centre Dr Nik Muhd Aslan Dr’s Clinic CRC: 03-8601 1079 (Tel) /
03-8601 1069 (Fax)
Pulau Pinang Hospital DR SOO HOO HWOEI FEN General line:
04-2225 333
CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586

 

Prostate Cancer

TYPE TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Metastatic Castration-Sensitive Prostate Cancer, Deleterious Germline or Somatic Hmologous Recombinatin Repair Gene-Mutated A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration- Sensitive Prostate Cancer (mCSPC) (AMPLITUDE) Kuala Lumpur Hospital (HKL) DR PRATHEPAMALAR A/P YEHGAMBARAM prathepa82@gmail.com General line: 03 – 2615 5555
CRC: 03 – 2615 5555 Ext. 6262 (Tel) /  crc.hkl@moh.gov.my (email) /
Crc Hkl / Clinical Research Centre HKL (Facebook)
SC: Amirah 017-233 6295
CLICK HERE
Sarawak General Hospital DR HADI BIN AB.JALIL hadiabjalil@gmail.com General line: 082 – 276666
CRC: 082-276820 (Tel) /
082-276823 (Fax) /
Tiong Lee Len, Admin Manager leelen.crc@gmail.com (Email) / https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480/ (Facebook)
National Cancer Institute (IKN) DR ARNIL GEORGE SIRIMANNE dranil@nci.gov.my General line : 03 – 8892 5555
CRC: 03 – 8892 5555
Ext 4168 (Tel) /
03- 8892 5622 (Fax) /
Siti Fatimah Zahra Mohd Anuar Pengurus Pentadbiran fatimahzahra@crc.moh.gov.my (Email)
Pulau Pinang Hospital DR FONG CHIN HENG fongchinheng@gmail.com  General line: ’04-2225 333
CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586 –
Dr. Yoon Chee Kin, Ketua Jabatan  dryoonck@moh.gov.my (email)
Sister Zarina Bt Che Umar
Admin Manager zarinacu@gmail.com (Email)
University of Malaya Medical Centre (UMMC) DR MARNIZA SAAD marniza@ummc.edu.my SC: Cryst Sari 03-79492120
(Research Room)

 

Renal Cancer

TYPE TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Advanced Clear Cell Renal Cell Carcinoma (ccRCC) An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or
MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC) (MK6482-012)
University of Malaya Medical Centre (UMMC) DR MARNIZA SAAD marniza@ummc.edu.my SC: Cryst Sari 03-79492120
(Research Room)
CLICK HERE
Kuala Lumpur Hospital (HKL) DR IBTISAM MUHAMAD NOR maryamsofiyyah@yahoo.com.my General line: 03 – 2615 5555
CRC: 03 – 2615 5555 Ext. 6262 (Tel) /  crc.hkl@moh.gov.my (email) /
Crc Hkl / Clinical Research Centre HKL (Facebook)
National Cancer Institute (IKN) DR SUHANA BINTI YUSAK  drsuhana@nci.gov.my General line : 03 – 8892 5555
CRC: 03 – 8892 5555 Ext 4168 (Tel) /
03- 8892 5622 (Fax) /
Siti Fatimah Zahra Mohd
Anuar Pengurus Pentadbiran fatimahzahra@crc.moh.gov.my (Email)
Sultan Ismail Hospital, Johor Bahru DR LIM CHUN SEN chunsen1@hotmail.com General line: 07 – 356 5000
CRC:  07 – 356 5155 (Tel) /
07 – 3565 5154 (Fax) /
Sister Rafi’ah binti Othman
Admin Manager crchsijb@gmail.com (Email)

Breast Cancer

TYPE TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Breast Cancer Studies of Epigenetic Changes in Blood Samples in Breast Cancer Patients (EPIGENECTIC) Kuala Lumpur Hospital (HKL) Dr Ros Suzanna Ahmad Bustamam rossuzanna@gmail.com
03-26155810
General line: 03 – 2615 5555
CRC: 03 – 2615 5555
Ext. 6262 (Tel) /
crc.hkl@moh.gov.my (email) /
Crc Hkl / Clinical Research Centre HKL (Facebook)
N/A
University of Malaya Medical Centre (UMMC) Dr Ho Gwo Fuang
fuang@ummc.edu.​my
SC: Alice 03-79492120
(Research Room)
HER2+ Advanced Breast Cancer in Asian Women Prospective study of UDP-gluconoryltransferase (UGT) 2B17 genotype as a predictive marker of exemestane pharmacokinetics and pharmacodynamics in Asian women with hormone receptor-positive advanced breast cancer (EXEMASTANE) University of Malaya Medical Centre (UMMC) Dr Ho Gwo Fuang
fuang@ummc.edu.​my
SC: Yok Yong 03-79492120
(Research Room)
CLICK HERE

 

Prostate Cancer

TYPE TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Metastatic Prostate Cancer Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer (Observational) (PREVALENCE) Sarawak General Hospital DR HADI BIN AB.JALIL hadiabjalil@gmail.com ‘General line: 082 – 276666
CRC: 082-276820 (Tel) /
082-276823 (Fax) /
Tiong Lee Len, Admin Manager leelen.crc@gmail.com (Email) / https://www.facebook.com/Clinical-Research-Centre-Sarawak-General-Hospital-105012171258480/ (Facebook)
CLICK HERE
Kuala Lumpur Hospital (HKL) DR MUTHUKKUMARAN A/L THIAGARAJAN drmuthuk@gmail.com General line: 03 – 2615 5555
CRC: 03 – 2615 5555 Ext. 6262 (Tel) /  crc.hkl@moh.gov.my (email) /
Crc Hkl / Clinical Research Centre HKL (Facebook)  SC: Amirah 017-233 6295
University of Malaya Medical Centre (UMMC) DR MARNIZA SAAD marniza@ummc.edu.my SC: Cryst Sari 03-79492120
(Research Room)
Pulau Pinang Hospital DR SOO HOO HWOEI FEN hwoeifen@yahoo.com General line: 04-2225 333
CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586
Dr. Yoon Chee Kin,
Ketua Jabatan
dryoonck@moh.gov.my (email)
Sister Zarina Bt Che Umar
Admin Manager
zarinacu@gmail.com (Email)

 

Lung Cancer

TYPE TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Advanced Non Small Cell Lung Cancer with EGFR mutation on Dacomitinib as First Line Treatment for Asian Patients (Observational) Real-World Utilization and Outcomes with Dacomitinib First-Line Treatment for EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer among Asian Patients – A Multi-Center Chart Review (ARIA) University of Malaya Medical Centre (UMMC) Dr Ho Gwo Fuang fuang@ummc.edu.​my SC: Wei Ying
03-79492120
(Research Room)
CLICK HERE
Pantai Hospital Kuala Lumpur DR JOHN LOW SENG HOOI john.low@pantaidr.my General Line:
03 – 2296 0888
CRC: 03 – 2781 0888
Ext 4519/4520/4522
Beacon Hospital Sdn Bhd DR THO LYE MUN drtho.oncology@gmail.com General line:
03 7620 7979 / 03 7787 2992
CRC: 03 -7787 2854 (Tel) / clinicalresearch@beaconhospital.com.my (Email)
Non Small Cell Lung Cancer with ALK Inhibitor Resistant in Asian (Liquid Biopsy) Plasma Molecular Profiling in ALK inhibitor resistant non-small cell lung cancer (ARTOG-004) Pantai Hospital Kuala Lumpur DR THO LYE MUN drtho.oncology@gmail.com General Line: 03 – 2296 0888 CRC: 03 – 2781 0888 Ext 4519/4520/4522 CLICK HERE
University of Malaya Medical Centre (UMMC) Dr Ho Gwo Fuang fuang@ummc.edu.​my SC: Yok Yong
03-79492120 (Research Room)
Non Small Cell Lung Cancer in Asian (Observational) A prospective, molecular profiling study of mutational genes in Asian patients with Non-Small Cell Lung Cancer. (Non-interventional study) (ATORG001) Pantai Hospital Kuala Lumpur DR THO LYE MUN drtho.oncology@gmail.com General Line: 03 – 2296 0888
CRC: 03 – 2781 0888
Ext 4519/4520/4522
CLICK HERE
University of Malaya Medical Centre (UMMC) Dr Ho Gwo Fuang fuang@ummc.edu.​my SC: Yok Yong
03-79492120 (Research Room)
SC: Wei Ying
03-79492120 (Research Room)
Beacon Hospital Sdn Bhd Dr Azura Rozila Ahmad General line: 03 7620 7979 / 03 7787 2992
CRC: 03 -7787 2854 (Tel) / clinicalresearch@beaconhospital.com.my (Email)
Malaysia, Non Small Cell Lung Cancer, Advnced or Metastatic A Prospective, Multicentre, Genomic Profiling Study In Patients With Locally Advanced Or Metastatic Non-small Cell Lung Cancer (NSCLC) In Malaysia Using Foundation Medicine (ML41262) Beacon Hospital Sdn Bhd DR THO LYE MUN drtho.oncology@gmail.com General line:
03 7620 7979 / 03 7787 2992
CRC: 03 -7787 2854 (Tel) / clinicalresearch@beaconhospital.com.my (Email)
N/A
Non-Small Cell Lung Cancer, Locally Advanced or Metastatic Genomic Profiling Study In Subjects With Locally Advanced/Metastatic Non-Small Cell Lung Cancer (ROCHE) Kuala Lumpur Hospital (HKL) Dr Ros Suzanna Ahmad Bustamam rossuzanna@gmail.com General line: 03 – 2615 5555
CRC: 03 – 2615 5555
Ext. 6262 (Tel) /
crc.hkl@moh.gov.my (email) /
Crc Hkl / Clinical Research Centre HKL (Facebook)
N/A
Malaysia, Non Small Cell Lung Cancer, Advnced or Metastatic A Prospective, Multicentre, Genomic Profiling Study In Patients With Locally Advanced Or Metastatic Non-small Cell Lung Cancer (NSCLC) In Malaysia Using Foundation Medicine (ML41262) Beacon Hospital Sdn Bhd DR THO LYE MUN drtho.oncology@gmail.com General line:
03 7620 7979 / 03 7787 2992
CRC: 03 -7787 2854 (Tel) / clinicalresearch@beaconhospital.com.my (Email)
N/A

 

Cervical Cancer Ovarian Clear Cell Carcinoma N

TYPE TITLE SITE PRINCIPAL INVESTIGATOR CONTACT LINKS
Metastatic and/or Recurrent Disease Asian Multicenter Prospective Study of Circulating Tumor DNA Sequencing (A-TRAIN) University of Malaya Medical Centre (UMMC) CLICK HERE
Kuala Lumpur Hospital (HKL)
Sarawak General Hospital
National Cancer Institute (IKN)

The information above was last updated on 29 October 2022.

Source: http://clinicalresearch.my/

Links are from CLINICALTRIAL.GOV